2-氨基-5-溴苯并噻唑 | 20358-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-氨基-5-溴苯并噻唑
• 中文别名: 5-溴噻唑-2-胺；2-氨基-5-溴噻唑
• 英文名称: 5-bromobenzo[d]thiazol-2-amine
• 英文别名: 2-amino-5-bromobenzothiazole；5-bromo-2-aminobenzothiazole；5-bromo-1,3-benzothiazol-2-amine
• CAS: 20358-03-6
• 化学式: C₇H₅BrN₂S
• mdl: MFCD00577806
• 分子量: 229.1
• InChiKey: ZPUJTWBWSOOMRP-UHFFFAOYSA-N

物化性质

• 熔点：
  194-198 °C
• 沸点：
  366.8±34.0 °C(Predicted)
• 密度：
  1.836±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• WGK Germany：
  3
• 海关编码：
  2934999090
• 安全说明：
  S26,S36
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H317,H319,H335
• 储存条件：
  室温

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 2-Amino-5-bromobenzothiazole
CAS-No. : 20358-03-6
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Skin irritation (Category 2)
Eye irritation (Category 2)
Skin sensitization (Category 1)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H315 Causes skin irritation.
H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust.
P280 Wear protective gloves.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C7H5BrN2S
Molecular Weight : 229,1 g/mol
Component Concentration
2-Amino-5-bromobenzothiazole
CAS-No. 20358-03-6 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Sulphur oxides, Hydrogen bromide gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 194 - 198 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,84
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
May cause sensitization by skin contact.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

制备方法

1. 在烧瓶中加入75克（0.5摩尔）苯基硫尿及750毫升氯仿，搅拌并控制反应温度在15~20℃，大约需要5小时。随后，滴加350毫升氯仿溶解的192克（1.2摩尔）溴溶液。加完后继续搅拌1小时。滤出浅橙色（溴过量沾染）的2-氨基-5-溴苯并噻唑溴氢酸盐。将上述溴氢酸盐溶于1.5升热水中，脱色过滤，加热至90℃，用浓氨水调节pH值约为9，趁热滤出结晶，并以热水浸洗两次，从而除去了未溴化的2-氨基苯并噻唑。

2. 在另一个烧瓶中加入75克（0.5摩尔）2-氨基苯并噻唑、75毫升冰乙酸，搅拌并控制反应温度在20~25℃。慢慢滴加80克（0.5摩尔）溴素溶解于50毫升冰乙酸的溶液。加完后继续搅拌1小时。将反应物移入至10升小缸中，加入3升水，搅拌下用氨水中和至pH值约为9，过滤、水洗并风干后得到产物100克。此产物可以用50%稀乙醇重结晶。

合成制备方法

1. 在烧瓶中加入75克（0.5摩尔）苯基硫尿及750毫升氯仿，搅拌并控制反应温度在15~20℃，大约需要5小时。随后滴加350毫升氯仿溶解的192克（1.2摩尔）溴溶液。加完后继续搅拌1小时。滤出浅橙色（溴过量沾染）的2-氨基-5-溴苯并噻唑溴氢酸盐。将上述溴氢酸盐溶于1.5升热水中，脱色过滤，加热至90℃，用浓氨水调节pH值约为9，趁热滤出结晶，并以热水浸洗两次，从而除去了未溴化的2-氨基苯并噻唑。

2. 在另一个烧瓶中加入75克（0.5摩尔）2-氨基苯并噻唑、75毫升冰乙酸，搅拌并控制反应温度在20~25℃。慢慢滴加80克（0.5摩尔）溴素溶解于50毫升冰乙酸的溶液。加完后继续搅拌1小时。将反应物移入至10升小缸中，加入3升水，搅拌下用氨水中和至pH值约为9，过滤、水洗并风干后得到产物100克。此产物可以用50%稀乙醇重结晶。

反应信息

• 作为反应物：
  描述：

  2-氨基-5-溴苯并噻唑 在 亚硝酸异戊酯 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 5-溴苯并噻唑
  参考文献：
  名称：

  铁催化串联氧化偶联和乙缩醛水解反应制备甲酰化苯并噻唑和异喹啉

  摘要：

  醛基是合成化学中最通用的中间体之一，并且将醛基引入杂芳烃对于分子结构的转化很重要。在这里，我们实现了苯并噻唑/莱和异喹啉的直接甲酰化。该反应具有新颖的铁催化的Minisci型氧化偶联工艺，该工艺使用可商购的1,3-二氧戊环作为甲酰化试剂，然后进行乙缩醛水解而无需分离过程。该反应可以在非常温和的反应条件下进行，并且表现出宽泛的官能团耐受性。

  DOI：

  10.1039/d1cc00621e
• 作为产物：
  描述：

  m-bromoaniline hydrochloride 在 盐酸 、 溴 作用下， 以 氯仿 、 水 为溶剂， 反应 4.5h， 生成 2-氨基-5-溴苯并噻唑
  参考文献：
  名称：

  合成的3-（1,3-苯并噻唑-2-基）2-苯基喹唑啉-4（3 H）-作为强效抗菌剂的QSAR建模

  摘要：

  目前的通讯引发了作为潜在抗菌剂的3-（1,3-苯并噻唑-2-基）2-苯基喹唑啉-4（3 H）-one的设计和合成。[（ -一个数字取代的2-苯并噻唑氨基的，2-氨基-5- ë） -苯基二氮烯基]苯甲酸，和2-苯基-4- ħ恶嗪-4-酮合成为苯并[d] [1,3]前体基板。这些化合物以极高的收率合成，并且根据IR，1证实了结构1 H NMR，质量和元素分析数据。体外筛选了这些化合物对革兰氏阳性和革兰氏阴性细菌代表菌群的抗菌活性，并通过定量结构-活性关系（QSAR）建立了模型，并使用顺序回归程序确定了由于结构和取代作用而引起的活性贡献。抗菌测定数据表明，发现合成的化合物表现出深远的抗菌活性。

  DOI：

  10.1007/s00044-011-9626-0
• 作为试剂：
  描述：

  1-(3-溴苯基)-2-硫脲 、 溴 在 水 、 二氯甲烷 、 正己烷 、 乙酸乙酯 、 2-氨基-5-溴苯并噻唑 作用下， 以 氯仿 为溶剂， 反应 18.5h， 以to obtain the title compound (Intermediate 63, 609 mg)的产率得到2-氨基-5-溴苯并噻唑
  参考文献：
  名称：

  Substituted phenylalkanoic acid derivatives and use thereof

  摘要：

  化合物的化学式为（I）或其盐：其中n表示1至3的整数，R表示具有3至8个碳原子的烷基基团，以及以下化学式表示的基团：R1(CH2)k-（其中k表示0或1至3的整数；R1表示具有3至7个碳原子的饱和环烷基团或具有6至8个碳原子的饱和紧缩环烷基团，且基团R1可被1至4个碳原子的低烷基基团取代），以及类似的基团；Ar表示紧缩双环基团，例如萘-1-基团，具有抑制前列腺素和白三烯产生的作用，并且对于预防和/或治疗由这些脂质介质引起的各种炎症性疾病等非常有用。

  公开号：

  US06867320B2

文献信息

• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2016046530A1

  公开（公告）日：2016-03-31

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

  本发明涉及新型化合物和制备去泛素化酶（DUBs）抑制剂的方法。具体而言，本发明涉及抑制泛素C端水解酶L1（UCHL1）。本发明进一步涉及在癌症和其他适应症治疗中使用DUB抑制剂。本发明的化合物包括具有式（I）或其药用可接受盐的化合物，其中R1至R8如本文所定义。
• Visible-light photoredox catalytic approach for the direct synthesis of 2-aminobenzothiazoles from anilines
  作者：Manjula Singh、Lal Dhar S. Yadav、Rana Krishna Pal Singh

  DOI：10.1016/j.tetlet.2020.151700

  日期：2020.3

  A novel, highly efficient and convenient approach for the visible-light-promoted direct synthesis of 2-aminobenzothiazoles from anilines and ammonium thiocyanate is presented. The reaction involves addition/cyclization cascade of SCN radical and anilines under photoredox catalysis with Ru(bpy)3Cl2. The salient features of the protocol include the utilization of atmospheric oxygen and visible light

  提出了一种新颖，高效，便捷的方法，用于可见光促进苯胺和硫氰酸铵直接合成2-氨基苯并噻唑。该反应涉及在Ru（bpy）3 Cl 2的光氧化还原催化下，SCN自由基和苯胺的加成/环化级联。该协议的显着特征包括在室温下利用大气中的氧气和可见光作为清洁，廉价和可持续的资源。
• Targeting mPGES-1 by a Combinatorial Approach: Identification of the Aminobenzothiazole Scaffold to Suppress PGE₂ Levels
  作者：Maria G. Chini、Assunta Giordano、Marianna Potenza、Stefania Terracciano、Katrin Fischer、Maria C. Vaccaro、Ester Colarusso、Ines Bruno、Raffaele Riccio、Andreas Koeberle、Oliver Werz、Giuseppe Bifulco

  DOI：10.1021/acsmedchemlett.9b00618

  日期：2020.5.14

  of inflammation and cancer pathologies. Starting from an aminobenzothiazole scaffold, used as an unprecedented chemical core for mPGES-1 inhibition, a Combinatorial Virtual Screening campaign was conducted, using the X-ray crystal structure of human mPGES-1. Two combinatorial libraries (6 × 104) were obtained by decorating the aminobenzothiazole scaffold with all acyl chlorides and boronates available

  微粒体前列腺素E2合酶1（mPGES-1）是负责诱导型前列腺素E2产生的末端酶，已成为治疗炎症和癌症的诱人靶标。从用作mPGES-1抑制作用的空前化学核心的氨基苯并噻唑支架开始，利用人mPGES-1的X射线晶体结构进行了组合虚拟筛选运动。通过用Merck数据库中可用的所有酰氯和硼酸酯修饰氨基苯并噻唑支架，获得了两个组合库（6×104）。科学的多学科方法包括虚拟筛选工作流程，合成和生物学评估，并导致鉴定出三种新型的mPGES-1抑制剂氨基苯并噻唑1、3和13。
• 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도
  申请人：KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY 한국과학기술연구원(319980077518) BRN ▼209-82-03522

  公开号：KR20200076655A

  公开（公告）日：2020-06-29

  본 발명은 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체(hydrazone derivatives) 및 이의 용도에 관한 것이다.

  这项发明涉及末端氨基被芳基或杂芳基取代的新的腙衍生物(hydrazone derivatives)及其用途。
• Discovery and Structure–Activity Relationships of <i>N</i> ‐Aryl 6‐Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors
  作者：Nicolas Boutard、Arkadiusz Białas、Aleksandra Sabiniarz、Paweł Guzik、Katarzyna Banaszak、Artur Biela、Marcin Bień、Anna Buda、Barbara Bugaj、Ewelina Cieluch、Anna Cierpich、Łukasz Dudek、Hans‐Michael Eggenweiler、Joanna Fogt、Monika Gaik、Andrzej Gondela、Krzysztof Jakubiec、Mirek Jurzak、Agata Kitlińska、Piotr Kowalczyk、Maciej Kujawa、Katarzyna Kwiecińska、Marcin Leś、Ralph Lindemann、Monika Maciuszek、Maciej Mikulski、Paulina Niedziejko、Alicja Obara、Henryk Pawlik、Tomasz Rzymski、Magdalena Sieprawska‐Lupa、Marta Sowińska、Joanna Szeremeta‐Spisak、Agata Stachowicz、Mateusz M. Tomczyk、Katarzyna Wiklik、Łukasz Włoszczak、Sylwia Ziemiańska、Adrian Zarębski、Krzysztof Brzózka、Mateusz Nowak、Charles‐Henry Fabritius

  DOI：10.1002/cmdc.201800569

  日期：2019.1.8

  is the ubiquitous and hypoxia‐induced isoform of PFK‐2, are reported. X‐ray crystallography and docking were instrumental in the design and optimisation of a series of N‐aryl 6‐aminoquinoxalines. The most potent representative, N‐(4‐methanesulfonylpyridin‐3‐yl)‐8‐(3‐methyl‐1‐benzothiophen‐5‐yl)quinoxalin‐6‐amine, displayed an IC50 of 14 nm for the target and an IC50 of 0.49 μm for fructose‐2,6‐biphosphate

  癌细胞的能量和生物质生产在很大程度上被有氧糖酵解所支持，这就是所谓的Warburg效应。该过程受关键酶的调节，其中磷酸果糖激酶PFK-2通过产生果糖-2,6-二磷酸而起重要作用。磷酸果糖激酶PFK-1执行的最有效的糖酵解限速步骤激活剂。本文介绍了6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酯酶3（PFKFB3）的新型抑制剂的合成，生物学评估以及其结构与活性之间的关系，PFKFB3是一种普遍存在且由低氧引起的PFK-2亚型，被报道。X射线晶体学和对接有助于设计和优化一系列N-芳基6-氨基喹喔啉。最有力的代表，N-（4-甲磺酰基吡啶-3-基）-8-（3-甲基-1-苯并噻吩-5-基）喹喔啉-6-胺，目标物的IC 50为14 n m，0.4的IC 50为0.49μm m为人类结肠癌HCT116细胞中果糖2,6-二磷酸的产生。这项工作为PFKFB3抑制剂领域的发展提供了新的机会。